Genetic dissection of melanoma pathways in the mouse

Seminars in Cancer Biology

Volumn 11, Issue 3, 2001, Pages 261-268

  Clarissa Yang, F ^a   Merlino, Glenn ^b   Chin, Lynda ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

16INK4a; H RASV12G; INK4; Melanoma; Mouse model; p19ARF; p53; RB

Indexed keywords

GENE PRODUCT; PROTEIN P16; PROTEIN P19; PROTEIN P53;

CANCER GENETICS; CANCER MODEL; CARCINOGENESIS; CELL TRANSFORMATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MELANOCYTE; MELANOMA; NONHUMAN; ONCOGENE C MYC; ONCOGENE RAS; REVIEW;

EID: 0034936840     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2000.0376     Document Type: Article

References (72)

1. IARC monographs on the evaluation of carcinogenic risks to humans. Solar and ultraviolet radiation
2. Melanoma and sun exposure: An overview of published studies
3. The pathogenesis of melanoma induced by ultraviolet radiation
4. Human cancer syndromes: Clues to the origin and nature of cancer
5. Molecular genetics of familial cutaneous melanoma
6. Genetics of melanoma
7. A cell cycle regulator potentially involved in genesis of many tumor types
8. Splicing into senescence: The curious case of p16 and p19ARF
9. The INK4a/ARF tumor suppressor: One gene-two products-two pathways
10. The INK4A/ARF locus and its two gene products
11. The retinoblastoma protein and cell cycle control
12. Cancer cell cycles
13. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
14. Functional and physical interactions of the ARF tumor suppressor with p53 and MDm2
15. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
16. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
17. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2
18. CDK inhibitors: Positive and negative regulators of G1-phase progression
19. Selective deletion of exon 1 beta of the p19ARF gene in metastatic melanoma cell lines
20. Homozygous deletion of the p16INK4a and the p15INK4b tumor suppressor genes in a subset of human sporadic cutaneous malignant melanoma
21. Retention of the CDKN2A locus and low frequency of point mutations in primary and metastatic cutaneous malignant melanoma
22. Mutations of p16 and p15 tumor suppressor genes and replication errors contribute independently to the pathogenesis of sporadic malignant melanoma
23. p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma
24. Germline p16 mutations in familial melanoma
25. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds
26. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: Analysis of a clinic-based population
27. CDKN2A germline mutations in UK patients with familial melanoma and multiple primary melanomas
28. Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: A clinic-based population study
29. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets
30. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France
31. Complex structure and regulation of the P16(MTS1) locus
32. A novel p16INK4A transcript
33. A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies
34. Frequent aberrant methylation of p16INK4a in primary rat lung tumors
35. Cloning and characterization of the CDKN2A and p19ARF genes from Monodelphis domestica
36. Transcriptional repression. The cancer-chromatin connection
37. The p16INK4a/CDKN2A tumor suppressor and its relatives
38. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene
39. Role of the INK4a locus in tumor suppression and cell mortality
40. The tumor suppressor protein p16INK4a
41. Analysis of ras mutations in human melanocytic lesions: Activation of the ras gene seems to be associated with the nodular type of human malignant melanoma
42. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo
43. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia
44. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF
45. Tumor spectrum in ARF-deficient mice
46. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
47. Mutation and expression of the p53 gene in human malignant melanoma
48. Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma
49. Absence of p53 gene mutations in cutaneous melanoma
50. Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions
51. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type
52. p53 gene mutation and expression in naevi and melanomas
53. p53 mutations in human cutaneous melanoma correlate with sun exposure by are not always involved in melanomagenesis
54. Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma
55. Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites
56. Aberrant expression of p53 gene product in malignant melanoma
57. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumor suppressor p16INK4a
58. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
59. Max interacting protein 1: Loss of heterozygosity is frequent in desmoplastic melanoma
60. Suppression of Myc, but not E1a, transformation activity by Max-associated proteins, Mad and Mxil
61. Activation of cyclin-dependent kinases by Myc mediates induction of cyclin A, but not apoptosis
62. Participation of cyclin A in Myc-induced apoptosis
63. Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle
64. Identification of CDK4 as a target of c-MYC
65. Cdc25 cell-cycle phosphatase as a target of c-myc
66. Myc-enhanced expression of Cull promoters ubiquitin-dependent proteolysis and cell cycle progression
67. Skin cancer
68. A theory of the etiology, and pathogenesis of human cutaneous malignant melanoma
69. Influence of sun exposures during childhood and during adulthood on melanoma risk
70. Metastatic cutaneous melanoma promoted by ultraviolet radiation in mice with transgene-initiated low melanoma susceptibility
71. Induction of melanoma of TPras transgenic mice
72. Accelerated ultraviolet radiation-induced carcinogenesis in hepatocyte growth factor/scatter factor transgenic mice